Nasal-type natural killer cell lymphoma preceded by benign panniculitis arising in an asymptomatic HTLV-1 carrier

Int J Dermatol. 2003 Sep;42(9):710-4. doi: 10.1046/j.1365-4362.2003.01757.x.

Abstract

We report a case of an Epstein-Barr virus (EBV)-associated nasal-type natural killer cell lymphoma (NKCL) preceded by benign panniculitis, which arose in a 48-year-old woman with an asymptomatic human T-cell leukemia/lymphoma virus type-1 (HTLV-1) infection. A biopsy of the initial panniculitis lesion demonstrated lobular panniculitis with a germinal center composed of benign mononuclear cells with a phenotype of CD4+CD45RO+CD5sCD3+ cCD3 epsilon + T-cell intracellular antigen-1 (TIA-1)- and granzyme B-. One year after oral prednisolone therapy, the patient developed subcutaneous nodules composed of atypical lymphoid cells with a phenotype of CD4-CD45RO+CD56+sCD3-cCD3 epsilon + (TIA-1)+ and granzyme B+. In the initial panniculitis lesion, neither EBV-encoded RNA (EBER-1) nor clonal proliferation of EBV-infected cells was identified. In later lesions, however, a large number of atypical cells were positive for EBER-1, and a clonal expansion of EBV-infected cells was detected. No clonal rearrangement of T-cell receptor-alpha, -beta, or -gamma genes was found in either specimen. This patient was an asymptomatic carrier of human T-cell leukemia/lymphoma virus type-1 (HTLV-1) without clonal integration of proviral HTLV-1 in neither the peripheral blood nor the skin lesions. These observations suggest that EBV-associated NKCL occurred subsequently in the clinical course of benign panniculitis under the influence of immunosuppression caused by prednisolone treatment and HTLV-1 infection.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Viral / analysis
  • Antibodies, Viral / blood
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brain Neoplasms / secondary
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Diagnosis, Differential
  • Doxorubicin / administration & dosage
  • Fatal Outcome
  • Female
  • Human T-lymphotropic virus 1 / immunology
  • Human T-lymphotropic virus 1 / isolation & purification
  • Humans
  • Immunocompromised Host
  • Lymphoma, T-Cell, Cutaneous / complications
  • Lymphoma, T-Cell, Cutaneous / diagnosis*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Lymphoma, T-Cell, Cutaneous / therapy
  • Middle Aged
  • Panniculitis / complications*
  • Panniculitis / drug therapy
  • Prednisolone / adverse effects
  • Prednisone / administration & dosage
  • Skin Neoplasms / complications
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy
  • Thigh
  • Vincristine / administration & dosage

Substances

  • Antibodies, Viral
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • Prednisone

Supplementary concepts

  • CHOP protocol